A Phase II Trial Of Ofatumumab In Older (greater than or equal to 70 Years) Patients With Previously Untreated Low Or Intermediate Risk Indolent B-Cell Lymphomas.
Withdrawn prior to enrolment
Phase of Trial: Phase II
Latest Information Update: 14 Oct 2015
At a glance
- Drugs Ofatumumab (Primary)
- Indications B cell lymphoma; Follicular lymphoma
- Focus Biomarker; Registrational; Therapeutic Use
- 28 Sep 2011 Status changed from recruiting to withdrawn prior to recruitment as reported by ClinicalTrials.gov.
- 29 Jun 2011 Actual initiation date changed from Jan 2011 to jun 2011 as reported by ClinicalTrials.gov.
- 23 Mar 2011 Status changed from not yet recruiting to recruiting as reported by ClinicalTrials.gov.